In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

That treatment, called CAR-T therapy, had been a groundbreaking step forward for cancer patients.

Scientists have discovered a surprising link between leukemia and autoimmune diseases. A new study shows that certain genetic changes connected to leukemia can also create abnormal immune cells that ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

The approach relies on a specially engineered scaffold that links three naturally occurring cytokines known to promote immune memory.

Fifth-grader Levi Buxman of Wooster has amassed more than 4,000 beads signifying various aspects of treatment for B-cell ...

That superhero is a gene called TP53, and for decades scientists have known it as the “guardian of the genome.” In a healthy cell, TP53 acts like both a brake and an emergency stop button. When DNA ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

To turbocharge disease-specific immune responses in patients, CAR-T cells are produced by removing a person's immune T cells ...

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

The breakthrough, published Tuesday in the journal Cell, offers a promising new strategy to combat relapse, which occurs in more than half of patients following CAR-T therapy. The approach works by ...

Interim phase 1b data showed 100% partial response rate in efficacy-evaluable CLL/SLL (4/4) after a median of at least three prior treatment lines. In heavily pretreated MZL (n=5), three complete ...